Cynet Appoints MacKenzie Brown as Vice President of Threat Intelligence Strategy
Brown will be Cynet’s leading voice on adversary tactics to help partners understand and respond to threats fasterBOSTON, Feb. 02,...
Month: February 2026
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation TechniquesHOUSTON,...
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to...
Spectral AI to Participate in National Burn Awareness Week 2026 February 1–7, 2026
DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo...
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02,...
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well...
CorMedix Therapeutics Announces Share Repurchase Program
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Standard Dental Labs Announces Acquisition of BRLIT Dental Laboratory, Inc.
ORLANDO, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (“SDL”), a Florida-based dental laboratory platform focused on...
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
NeuroThera’s Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc...
Quotient Therapeutics Appoints Seasoned Life Sciences Executive, Susan Keefe, as Chief Financial Officer
CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to...
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its...
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the...
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”),...
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in...
Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians
Partnering with Texas pathology group enables a genetics-focused strategy to address the hidden epidemic of celiac diseaseIRVINE, Calif. and SAN...
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific PublicationsMARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) --...
DLH to Announce Fiscal 2026 First Quarter Financial Results
ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of...
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week...